NYSE:ABBVBiotechs
AbbVie (ABBV) Launches Boey In Europe With A Different Take On Wrinkle Injectables
Allergan Aesthetics, an AbbVie company, received European approval for Boey, a botulinum toxin serotype E injectable for glabellar lines.
Boey is described as a first in its class in Europe, with rapid onset and short duration properties that differ from existing neurotoxin options.
The launch expands AbbVie’s aesthetics portfolio, an important focus area for NYSE:ABBV following the loss of Humira exclusivity.
For AbbVie, aesthetics sit alongside immunology and oncology as a core business...